Viva Biotech Holdings (1873) AI Stock Analysis

• Market Cap: HK$3.19B
• Dividend Yield: N/A
• Average Volume (3M): 6.02M
• Price to Earnings (P/E): 17.9
• Beta (1Y): 2.22
• Revenue Growth: -9.75%
• EPS Growth: N/A
• Country: HK
• Employees: 2,063
• Sector: Healthcare
• Sector Strength: 42
• Industry: Biotechnology
• EPS (TTM): 0.03
• Shares Outstanding: 2,128,434,300
• 10 Day Avg. Volume: 6,178,950
• 30 Day Avg. Volume: 6,017,803
• PEG Ratio: 0.02
• Price to Book (P/B): 0.81
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 21.33
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 58 Neutral
• Price Target: HK$1.50 ▼(-0.66%Downside)

The stock of Viva Biotech Holdings scores a 58, primarily due to its mixed financial performance and moderate technical signals. The balance sheet strength is offset by cash flow volatility, while technical indicators suggest some bullish momentum but no clear trend. The valuation appears reasonable, but the absence of dividend yield is notable.

Viva Biotech Holdings Business Overview & Revenue Model

Company Description

Viva Biotech Holdings (stock code: 1873) is a China-based company primarily engaged in providing drug discovery services to biotechnology and pharmaceutical companies worldwide. The company operates in the sectors of Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO), offering a wide range of integrated services including structure-based drug discovery, medicinal chemistry, and drug development services. Viva Biotech leverages its proprietary technology platforms and experienced scientific team to accelerate the drug discovery process for its clients.

How the Company Makes Money

Viva Biotech Holdings generates revenue primarily through its drug discovery and development services as a CRO and CDMO. The company earns money by providing a range of services to pharmaceutical and biotechnology companies, including structure-based drug discovery, medicinal chemistry, and full-spectrum development services from preclinical to clinical stages. Key revenue streams include service fees for custom research projects and long-term collaborative partnerships with biotech firms. Viva Biotech also benefits from equity investments in client companies, which allow it to participate in the financial success of the drugs discovered and developed through its platforms. Strategic partnerships and continuous innovation in drug discovery technologies further enhance its revenue potential.

Viva Biotech Holdings Financial Statement Overview

Summary

Viva Biotech Holdings exhibits a mixed financial performance. Profitability metrics show signs of recovery, but inconsistencies in revenue and net income present challenges. The balance sheet remains robust with a solid equity base and manageable debt levels. However, cash flow volatility and recent declines in operating cash flow suggest potential liquidity concerns. The company should focus on stabilizing cash generation and enhancing profitability to strengthen its financial health.

Income Statement

The company's revenue has shown volatility over the years, with a decrease from 2022 to 2024. Gross profit margins have remained strong, averaging around 35%. Net income has improved in 2024 compared to the losses in previous years, signaling a recovery. However, net profit margins have been inconsistent, indicating potential profitability challenges.

Balance Sheet

The company has a stable equity position with a debt-to-equity ratio of 0.34 in 2024, lower than the previous year, indicating manageable leverage. The equity ratio remains above 50%, highlighting a solid financial foundation. However, the decrease in cash reserves over time suggests potential liquidity management issues.

Cash Flow

Operating cash flow has fluctuated significantly, with a concerning drop to zero in 2024. This instability raises questions about the company's ability to generate consistent cash flow from operations. The lack of free cash flow growth further indicates potential challenges in maintaining positive cash flow.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.99B	2.16B	2.38B	2.10B	696.96M
Gross Profit	687.40M	738.43M	815.68M	650.98M	304.87M
EBITDA	428.00M	391.01M	-89.04M	369.94M	-223.89M
Net Income	167.29M	-116.11M	-528.48M	287.55M	-386.88M
Balance Sheet
Total Assets	7.05B	7.45B	7.92B	8.04B	8.15B
Cash, Cash Equivalents and Short-Term Investments	941.58M	1.04B	678.57M	800.95M	2.36B
Total Debt	1.28B	1.90B	2.82B	2.65B	2.97B
Total Liabilities	3.23B	3.76B	4.32B	4.13B	4.40B
Stockholders Equity	3.80B	3.69B	3.60B	3.91B	3.76B
Cash Flow
Free Cash Flow	182.32M	195.57M	136.72M	-487.35M	-549.44M
Operating Cash Flow	373.99M	383.40M	386.05M	77.83M	43.18M
Investing Cash Flow	185.90M	439.17M	-372.80M	-868.84M	-3.85B
Financing Cash Flow	-657.76M	-429.50M	-143.20M	-653.16M	5.31B

Viva Biotech Holdings Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1.51
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1873, the sentiment is Neutral. The current price of 1.51 is below the 20-day moving average (MA) of 1.69, below the 50-day MA of 1.63, and above the 200-day MA of 1.19, indicating a neutral trend. The MACD of -0.04 indicates Positive momentum. The RSI at 39.34 is Neutral, neither overbought nor oversold. The STOCH value of 15.26 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:1873.

Viva Biotech Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2696	76 Outperform	HK$27.31B	30.70	31.65%	―	4.23%	47.71%
Sector *	60 Neutral	HK$15.14B	5.55	-7.43%	4.45%	11.60%	-21.06%
1873	58 Neutral	HK$3.19B	17.89	4.47%	―	-9.75%	―
1877	51 Neutral	HK$33.78B	―	-19.78%	―	25.96%	39.58%
2157	49 Neutral	HK$9.84B	―	-51.40%	―	58.75%	-1310.16%

Viva Biotech Holdings Corporate Events

Viva Biotech Holdings Successfully Passes All Resolutions at Annual General Meeting

Viva Biotech Holdings announced that all resolutions were passed at its Annual General Meeting held on June 12, 2025. The resolutions included the adoption of financial statements, re-election of directors, authorization of director remuneration, re-appointment of auditors, and mandates related to share capital management. The successful passing of these resolutions reflects shareholder confidence and supports the company’s strategic direction, potentially impacting its operational and market positioning positively.

Viva Biotech Clarifies Details on Connected Transaction with Nanjing Entities

Viva Biotech Holdings has announced a supplemental update regarding a connected transaction involving the establishment of a limited partnership fund. The update clarifies that several Nanjing-based entities involved in the joint venture are controlled by the Nanjing Jiangbei New Area Management Committee, a governmental body. This announcement reinforces the company’s strategic positioning and potential influence in the biotechnology sector through governmental collaboration.

Viva Biotech Enters Joint Venture to Launch Pharmaceutical Investment Fund

Viva Biotech Holdings, through its subsidiary Hangzhou Viva Zongchen, has entered into a Joint Venture Agreement to establish a new Fund focused on private equity investments in the pharmaceutical industry. The Fund, which has a term of seven years, will concentrate on early-stage development projects and technological innovation in life sciences. Hangzhou Viva Zongchen will invest RMB25.0 million as a limited partner. This strategic move positions Viva Biotech to leverage emerging opportunities in the pharmaceutical sector, potentially enhancing its industry standing and offering growth prospects for stakeholders.

Viva Biotech Holdings Announces Annual General Meeting with Key Resolutions

Viva Biotech Holdings has announced its upcoming annual general meeting scheduled for June 12, 2025, in Shanghai, where key resolutions will be discussed. These include the adoption of financial statements, re-election of directors, and authorization for the board to fix directors’ remuneration and appoint auditors. The meeting will also consider authorizing the directors to issue additional shares, which could impact the company’s capital structure and market positioning.